FILING ANALYSIS · TUESDAY, NOVEMBER 10
Keenova Therapeutics plc KEEN — 8-K: Results of Operations and Financial Condition
positive
Keenova Therapeutics plc reported strong third-quarter 2026 financial results, with net sales from continuing operations of $550 million and adjusted EBITDA of $233 million, driven by growth in Acthar Gel and XIAFLEX, and raised its full-year net sales and adjusted EBITDA guidance. The company also announced progress in its XIAFLEX pipeline, including an expected sBLA submission for plantar fibrom
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →